| Autor: |
Porcu, Maurizio, Landis, Novella, Salis, Stefano, Corda, Marco, Orrù, Pierpaolo, Serra, Emanuela, Usai, Barbara, Matta, Gildo, Galanello, Renzo |
| Předmět: |
|
| Zdroj: |
European Journal of Heart Failure; Mar2007, Vol. 9 Issue 3, p320-322, 3p |
| Abstrakt: |
Abstract: Despite usual iron chelating therapy based on desferrioxamine, patients affected by β-thalassemia major (β-TM) often develop progressive heart failure caused by myocardial iron overload, which is the leading cause of mortality within the third decade of life. Heart transplantation is a limited therapeutic option, as very often these patients have multi-organ iron deposits and infective complications (particularly hepatitis C), secondary to frequent blood transfusions. We report the case of a 26-year-old male affected by β-TM with end-stage heart failure, who showed a dramatic improvement in symptoms and myocardial function when a new oral iron chelating agent, deferiprone, was added to standard therapy with desferrioxamine. [Copyright &y& Elsevier] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
